# 5. 510(k) SUMMARY

# Submitter's Name/Address

Submitter's Name:. Submitter's Address:

Phone:   
Fax:   
Establishment Registration Number:   
Owner/Operator Number: Tokyo Boeki Medisys Inc.   
1-14-21 Higashi-Toyota, Hino Tokyo 191-0052   
$+ 8 1$ -42-587-2965   
$+ 8 1$ -42-587-7781   
3004378324   
9060135

# Contact Person (United States Agent)

Name of Agent: Agent's Business Name: Street Address:

Phone:   
Fax:   
E-mail address:   
James M. Clinton   
Quality and Regulatory Consulting, LLC   
5105 Fairoaks Road   
Durham, NC 27712-2078   
919-247-0479   
919-287-2551   
clintonjm@earthlink.net

# Date of Preparation of this Summary: October 25, 2011

Device Trade or Proprietary Name:

Biolis 24i, MGC 240 and Prestige 24i, (These are the same models except the names)

Device Common Name:

Clinical Chemistry Analyzer (with optional ISE Module)

# Classification Numbers/Class:

75JJE, Class I   
75CFR Class II

# 510(k) Summary:

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(K) number is : k103531

# Description:

Using photometry, the Biolis 24i instrument measures the glucose concentration in serum by monitoring the change in absorbance at $3 4 0 \mathsf { n m }$ Additionally, the Biolis 24i with lon-Selective Elective module additionally measures the concentration of the electrolytes, sodium, potassium and chloride in serum, using indirect potentiometry.

# Intended Use:

The Biolis 24i Clinical Chemistry Analyzer is a discrete photometric clinical chemistry analyzer. The device is intended to duplicate manual analytical procedures by automating various steps such as piettng, heatg, measring color intesity, an reoring rus.The device is inte to bes with certain materials to measurevarious analytes of diagnostic interest including glucose. An optional lon Selective Electrode Module is intended to measure sodium, potassium and chloride.

The Biolis 24i analyzer with glucose hexokinase assay is intended to measure glucose quantitatively in human serum. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic glycemia, and of the pancreatic islet cell carcinoma.

# Substantial Equivalence:

Substantial equivalence has been demonstrated between the Beckman CX-7 (K904219) and the Biolis iThese analyzers are calibrated with known concentration calibrator material and both measure specific concentrations using photometry.

Comparison with predicate:   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New DeviceBiolis 24i</td><td rowspan=1 colspan=1>PredicateSYNCHRON CX 7 (K904219)</td></tr><tr><td rowspan=1 colspan=1>General</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>System Principle</td><td rowspan=1 colspan=1>Discrete, single line randomaccess, multi-test analysis</td><td rowspan=1 colspan=1>Discrete, random access,multi-test analysis</td></tr><tr><td rowspan=1 colspan=1>Throughput</td><td rowspan=1 colspan=1>240 tests</td><td rowspan=1 colspan=1>225 tests/hr (photometric only)</td></tr><tr><td rowspan=1 colspan=1>Configuration</td><td rowspan=1 colspan=1>Analytical unit, Control unit</td><td rowspan=1 colspan=1>Analytical unit, Control unit</td></tr><tr><td rowspan=1 colspan=1>Measurement modes</td><td rowspan=1 colspan=1>Absorbance</td><td rowspan=1 colspan=1>Absorbance</td></tr></table>

# Tokyo Boeki Medisys Inc.

<table><tr><td rowspan=1 colspan=1>Detector</td><td rowspan=1 colspan=1>Photo-diode</td><td rowspan=1 colspan=1>Diffraction grating, photodiodearray</td></tr><tr><td rowspan=1 colspan=1>Optical system</td><td rowspan=1 colspan=1>Wavelength range of 340 to800nm</td><td rowspan=1 colspan=1>340, 380, 410, 470, 520, 560,600, 650, 670, 700 nm</td></tr><tr><td rowspan=1 colspan=1>Light source</td><td rowspan=1 colspan=1>Tungsten halogen lamp</td><td rowspan=1 colspan=1>xenon</td></tr><tr><td rowspan=1 colspan=1>Reaction cuvettes</td><td rowspan=1 colspan=1>Plastics, semi disposal</td><td rowspan=1 colspan=1>quartz</td></tr><tr><td rowspan=1 colspan=1>Path length</td><td rowspan=1 colspan=1>8mm</td><td rowspan=1 colspan=1>5 mm</td></tr><tr><td rowspan=1 colspan=1>Reaction time</td><td rowspan=1 colspan=1>Maximum 10min.</td><td rowspan=1 colspan=1>Maximum 12 min.</td></tr><tr><td rowspan=1 colspan=1>Incubation temperature</td><td rowspan=1 colspan=1>37C +/- 0.1C</td><td rowspan=1 colspan=1>same</td></tr><tr><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Glucose hexokinase 510(k):k802810</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Quantitative determination ofglucose in serum</td><td rowspan=1 colspan=1>Quantitative determination ofglucose in serum plasma, urine,CSF</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric endpoint usingglucose hexokinase.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum, plasma, urine, CSF</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>3 uL</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Reaction Time</td><td rowspan=1 colspan=1>5 min Analysis timeRead period: 52 - 54 points(15 seconds per point)</td><td rowspan=1 colspan=1>5 min</td></tr></table>

The validated system is described below.

<table><tr><td rowspan=1 colspan=1>Analyzer:</td><td rowspan=1 colspan=1>Tokyo Boeki BioLis 24i Analyzer, software revision: 1.26Serial numbers are listed on individual data sheets.</td></tr><tr><td rowspan=1 colspan=1>Reagent:</td><td rowspan=1 colspan=1>Carolina Liquid Chemistries Glucose Reagent, Kit product no. BL-208 (alsopackaged as AU-208). Lot numbers are listed on individual data sheets.</td></tr><tr><td rowspan=1 colspan=1>Applicationparameters:</td><td rowspan=1 colspan=1>Sample volume: 3 Î¼LReagent volume: 310 pLWavelengths:   340 / 405 nmReaction type:  EndpointRead period:    52 - 54</td></tr><tr><td rowspan=2 colspan=1>Calibrator:</td><td rowspan=1 colspan=1>Pointe Scientific Chemistry Calibratorproduct no. C7506-50, lot 11802, exp. March 2014Premarket clearance reference no.: K070207</td></tr><tr><td rowspan=1 colspan=1>The 185 mg/dL glucose set point for the Pointe Calibrator was verified for theCarolina Liquid Chemistries Glucose Reagent by comparing the calibrator to NISTSRM 965b, Glucose in Frozen Serum. The Pointe Calibrator was assayed eighttimes over each of four analytical runs against NiST standard levels 3 and 4 whichwere each assayed in duplicate. The glucose concentration of the Pointe Calibratorwas calculated for each run by linear interpolation the NiST assay values and theirrespective certified values of 118.5 mg/dL and 294.5 mg/dL. The mean glucoseresult of the Pointe Calibrator over the four runs was 185.6 mg/dL.</td></tr></table>

# Performance Characteristics <Glucose Hexokinase >

# Method Comparison

A correlation analysis between the Beckman CX-7 and the Biolis 24i yielded the following results:

<table><tr><td rowspan=1 colspan=1>RepresentativeMethod</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>Slope(Least-Squares)</td><td rowspan=1 colspan=1>Y-axis intercept</td></tr><tr><td rowspan=1 colspan=1>GLU</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>0.974</td><td rowspan=1 colspan=1>2.22</td></tr></table>

# Precision

# Repeatability

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>106.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>116.8</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=1 colspan=1>Serum 4</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>192.1</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.1%</td></tr><tr><td rowspan=1 colspan=1>Serum 5</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>446.2</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>1.5%</td></tr></table>

# Total Imprecision Study

<table><tr><td rowspan=1 colspan=1>Analyzer s/n</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=4 colspan=1>2229450610</td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>63.2</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>118.1</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>188.8</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>447.0</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>2.3%</td></tr><tr><td rowspan=4 colspan=1>2227671109</td><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>63.2</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>117.6</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>2.3%</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>186.9</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>445.9</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>2.2%</td></tr></table>

# Linearity

The linearity test yielded the following results:

<table><tr><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>0.9982</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.948</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>2.45</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>25 - 500 mg/dL</td></tr></table>

# Sensitivity

mg/dL   

<table><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>3.64</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>5.64</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=1>10</td></tr></table>

# Interferences

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>InterferentConcentration</td><td rowspan=1 colspan=1>GlucoseConcentration</td><td rowspan=1 colspan=1>ObservedInterference</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>30 mg/L</td><td rowspan=1 colspan=1>75 mg/dL140 mg/dL</td><td rowspan=1 colspan=1>none</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>4.8 mg/dL6.4 mg/dL</td><td rowspan=1 colspan=1>90 mg/dL146 mg/dL</td><td rowspan=1 colspan=1>-3.3 mg/dL-3.6%</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>240 mg/dL160 mg/dL</td><td rowspan=1 colspan=1>76 mg/dL139 mg/dL</td><td rowspan=1 colspan=1>-3.6 mg/dL-3.8%*</td></tr><tr><td rowspan=1 colspan=1>Lipemia(from Intralipid)</td><td rowspan=1 colspan=1>600 mg/dL80 mg/dL</td><td rowspan=1 colspan=1>72 mg/dL142 mg/dL</td><td rowspan=1 colspan=1>+ 4 mg/dL+ 3.9%</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>24 mg/L48 mg/L</td><td rowspan=1 colspan=1>76 mg/dL139 mg/dL</td><td rowspan=1 colspan=1>+ 2.4 mg/dL+ 3.1%</td></tr><tr><td rowspan=1 colspan=1>Tetracycline</td><td rowspan=1 colspan=1>15 mg/L</td><td rowspan=1 colspan=1>76 mg/dL141 mg/dL</td><td rowspan=1 colspan=1>none</td></tr></table>

# Conclusion

The data demonstrates that Biolis 24i is substantially equivalent to Beckman SYNCHRON CX 7 (K904219) and that the CLC Glucose Reagent is substantially equivalent to Beckman Glucose Reagent (K802810).

Tokyo Boeki Medisys Inc. c/o James M Clinton US Agent 5105 Fairoaks Road, Durham, NC 27712

Re: k103531 Trade/Device Name: Biolis 24i Clinical Chemistry Analyzer Regulation Number: 21 CFR 862.1345 Regulation Name:Glucose test system Regulatory Class: II Product Code: CFR, JJE Dated: November 4, 2011 Received: November 8, 2011

Dear Mr. Clinton:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other . requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance..

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

2

Coupney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# INDICATIONS FOR USE

510(k) Number (if known): k103531

Device Name: Biolis 24i Clinical Chemistry Analyzer

Indications for Use:

The Biolis 24i Clinical Chemistry Analyzer is a discrete photometric clinical chemistry analyzer. The device is intended to duplicate manual analytical procedures by automating various steps such as pipetting, heating, measuring color intensity, and reporting results. The device is intended to be used with certain materials to measure various analytes of diagnostic interest including glucose.

The Biolis 24i analyzer with glucose hexokinase assay is intended to measure glucose quantitatively in human serum. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic glycemia, and of the pancreatic isle cell carcinoma.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/54d0328a7e9cb865e57379afffd26fc4190da471db1fce83cfc60d752c49e6c5.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety